Unknown statusInterventionalNot ApplicableLast updated Jan 12, 2023

Efficacy and Safety of SA58 Nasal Spray in Close Contact With COVID-19 People

A Randomized, Single-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray, Among Close Contact With COVID-19 People

Overview

ClinicalTrials.gov ID: NCT05667714
Lead Sponsor: Sinovac Life Sciences Co., Ltd.INDUSTRY
Brief Summary: This is a randomized, single-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of SA58 nasal spray in close contact with COVID-19 people.
Study Type: Interventional

Status

Overall Status: Unknown status
Start Date: Nov 26, 2022Actual
Primary Completion Date: Dec 30, 2022Actual
Completion Date: Mar 30, 2023Estimated

Study Record Dates

First Submitted: Dec 13, 2022
First Submitted that Met QC Criteria: Dec 27, 2022
First Posted: Dec 29, 2022Actual
Last Update Submitted that Met QC Criteria: Jan 11, 2023
Last Update Posted: Jan 12, 2023Actual
Last Verified: Dec 2022

NCT05664919Unknown status

Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray to Prevent Infection in High-risk Populations

NCT06048393Unknown status

SA55 Novel Coronavirus Broad-spectrum Neutralizing Antibody Nasal Spray in Health People

NCT06127498Unknown status

The Safety and Tolerability of A8G6 COVID-19 Neutralization Antibody Combined With Nasal Spray

NCT05977101Unknown status

The Safety and Tolerability of MY-586 COVID-19 Neutralizing Antibody Nasal Spray in Healthy Subjects

NCT05765279Completed

A Study to Assess the Efficacy of HH-120 Nasal Spray for Prevention of SARS-CoV-2 Infection in Adult Close Contacts of Individuals Infected With SARS-CoV-2

NCT05747677Completed

A Study of HH-120 Nasal Spray in Close Contacts of Those Diagnosed With COVID-19